TP53 in hematologic malignancies. In MDS patients, TP53 mutations, especially mutli-hit TP53 mutations, are associated with high-risk disease, rapid transformation to AML, and therapy resistance. This evidence concerns the gene TP53 and myelodysplastic syndrome.